[go: up one dir, main page]

MX2023013194A - Compuesto inhibidor de atr que contiene sulfoximina. - Google Patents

Compuesto inhibidor de atr que contiene sulfoximina.

Info

Publication number
MX2023013194A
MX2023013194A MX2023013194A MX2023013194A MX2023013194A MX 2023013194 A MX2023013194 A MX 2023013194A MX 2023013194 A MX2023013194 A MX 2023013194A MX 2023013194 A MX2023013194 A MX 2023013194A MX 2023013194 A MX2023013194 A MX 2023013194A
Authority
MX
Mexico
Prior art keywords
sulfoximine
inhibitor compound
atr inhibitor
atr
containing atr
Prior art date
Application number
MX2023013194A
Other languages
English (en)
Inventor
Baomin Liu
Kuo Gai
Wei Shi
Yinsheng Zhang
Yan Zhu
Shaowei Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2023013194A publication Critical patent/MX2023013194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto inhibidor de ATR que contiene sulfoximina tal como se representa mediante la fórmula (I), un método de preparación del mismo, una composición farmacéutica que lo contiene y el uso del mismo en el tratamiento de enfermedades y/o afecciones relacionadas con ATR o mediadas por ATR. (ver Fórmula).
MX2023013194A 2021-05-12 2022-05-12 Compuesto inhibidor de atr que contiene sulfoximina. MX2023013194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110517129 2021-05-12
PCT/CN2022/092494 WO2022237875A1 (zh) 2021-05-12 2022-05-12 含有亚磺酰亚胺基的atr抑制剂化合物

Publications (1)

Publication Number Publication Date
MX2023013194A true MX2023013194A (es) 2023-11-15

Family

ID=84028114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013194A MX2023013194A (es) 2021-05-12 2022-05-12 Compuesto inhibidor de atr que contiene sulfoximina.

Country Status (11)

Country Link
US (1) US20250026750A1 (es)
EP (1) EP4332103A4 (es)
JP (1) JP2024517906A (es)
KR (1) KR20240006579A (es)
CN (1) CN117295740A (es)
AU (1) AU2022271549A1 (es)
CA (1) CA3218346A1 (es)
IL (1) IL308409A (es)
MX (1) MX2023013194A (es)
TW (1) TW202311260A (es)
WO (1) WO2022237875A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
CN117867664B (zh) * 2023-12-25 2024-11-26 康龙化成(宁波)科技发展有限公司 一种On-DNA亚磺酰亚胺类化合物及其合成方法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102311448B (zh) * 2010-07-07 2014-02-19 中国科学院广州生物医药与健康研究院 噻吩并嘧啶酮类dpp-iv抑制剂
KR20140084112A (ko) * 2011-09-30 2014-07-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
HUE066043T2 (hu) * 2017-07-13 2024-07-28 Univ Texas A TR kináz beterociklusos inhibitorai
JP7341156B2 (ja) * 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
EP3828183A4 (en) * 2018-07-25 2022-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
CN111484491B (zh) * 2019-01-25 2022-09-02 四川科伦博泰生物医药股份有限公司 取代吡啶并环化合物、其制备方法和用途
GB201908885D0 (en) * 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds

Also Published As

Publication number Publication date
WO2022237875A1 (zh) 2022-11-17
AU2022271549A1 (en) 2023-11-16
CN117295740A (zh) 2023-12-26
EP4332103A4 (en) 2025-09-03
TW202311260A (zh) 2023-03-16
CA3218346A1 (en) 2022-11-17
US20250026750A1 (en) 2025-01-23
EP4332103A1 (en) 2024-03-06
IL308409A (en) 2024-01-01
JP2024517906A (ja) 2024-04-23
KR20240006579A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
MX2023013194A (es) Compuesto inhibidor de atr que contiene sulfoximina.
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
ECSP088784A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2023009011A (es) Inhibidor de cdk.
UY37997A (es) Agentes antivirales contra la hepatitis b
CO6460772A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
AR111495A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2017007293A2 (es) Dinucleótidos cíclicos útiles para el tratamiento de (inter alia) cáncer
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
DOP2012000312A (es) Triazolopiridinas sustituidas
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.
MX2023013515A (es) Inhibidores de la interaccion de menina-mll.
CO2022004978A2 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CO2022006965A2 (es) Inhibidores de egfr
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
PE20210123A1 (es) Compuesto de anillo de metillactama y uso farmaceutico del mismo